Technical Analysis for SLRN - Acelyrin Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| F | 4.24 | 0.00% | 0.00 |
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| NR7 | Range Contraction | 0.00% | |
| Narrow Range Bar | Range Contraction | 0.00% | |
| Doji - Bullish? | Reversal | 0.00% | |
| New 52 Week Low | Weakness | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| New 52 Week Closing Low | Bearish | 0.00% | |
| New 52 Week Low | Weakness | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Down 3 Days in a Row | Weakness | 0.00% |
| Alert | Time |
|---|---|
| Up 2% | about 6 hours ago |
| Possible NR7 | about 7 hours ago |
| Up 1% | about 10 hours ago |
| Fell Below Previous Day's Low | about 11 hours ago |
| Down 1% | about 11 hours ago |
Get this analysis on your stocks daily!
- Earnings date: 02/28/2024
Acelyrin Inc. Description
ACELYRIN, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis. It is also developing lonigutamab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody against insulin-like growth factor 1 receptor, which is in Phase 1 clinical trials for use in the treatment of thyroid eye disease; and SLRN-517, a fully human IgG1 monoclonal antibody targeting c-KIT, which is in preclinical stage for use in the treatment of chronic urticaria. The company was incorporated in 2020 and is headquartered in Agoura Hills, California.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Clinical Medicine Drugs Monoclonal Antibodies Uveitis Psoriatic Arthritis Hidradenitis Suppurativa Thyroid Eye Disease Chronic Urticaria Duligotuzumab
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 29.88 |
| 52 Week Low | 4.18 |
| Average Volume | 1,321,462 |
| 200-Day Moving Average | 11.54 |
| 50-Day Moving Average | 6.88 |
| 20-Day Moving Average | 5.46 |
| 10-Day Moving Average | 4.80 |
| Average True Range | 0.40 |
| RSI (14) | 20.63 |
| ADX | 45.89 |
| +DI | 7.38 |
| -DI | 34.79 |
| Chandelier Exit (Long, 3 ATRs) | 5.80 |
| Chandelier Exit (Short, 3 ATRs) | 5.39 |
| Upper Bollinger Bands | 6.99 |
| Lower Bollinger Band | 3.93 |
| Percent B (%b) | 0.1 |
| BandWidth | 56.08 |
| MACD Line | -0.73 |
| MACD Signal Line | -0.67 |
| MACD Histogram | -0.0682 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 4.48 | ||||
| Resistance 3 (R3) | 4.49 | 4.41 | 4.44 | ||
| Resistance 2 (R2) | 4.41 | 4.35 | 4.41 | 4.43 | |
| Resistance 1 (R1) | 4.33 | 4.31 | 4.29 | 4.32 | 4.41 |
| Pivot Point | 4.25 | 4.25 | 4.24 | 4.25 | 4.25 |
| Support 1 (S1) | 4.17 | 4.19 | 4.13 | 4.16 | 4.07 |
| Support 2 (S2) | 4.09 | 4.15 | 4.09 | 4.05 | |
| Support 3 (S3) | 4.01 | 4.09 | 4.04 | ||
| Support 4 (S4) | 4.00 |
